Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 9/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20474391 | 0.91 | TYMP (0.52) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL20481628 | 0.91 | TYMP (0.52) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL21750418 | 0.91 | TYMP (0.52) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL22577545 | 0.91 | TYMP (0.52) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL25379844 | 0.90 | TYMP (0.51) | TYMPTAS1R3TAS1R1KDM4EIMPDH2 | |
| SCHEMBL18490221 | 0.90 | TYMP (0.51) | TYMPTAS1R3TAS1R1KDM4EIMPDH2 | |
| SCHEMBL30524667 | 0.90 | TYMP (0.51) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL21878006 | 0.90 | TYMP (0.51) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL29881756 | 0.90 | TYMP (0.51) | TYMPTAS1R3TAS1R1KDM4EIMPDH2 | |
| SCHEMBL18490534 | 0.90 | TYMP (0.51) | TYMPTAS1R3TAS1R1KDM4EIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 2012/4885TAS1R3 443/4885TAS1R1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.